Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.”
The recent Facial and Rhinoplasty Symposium was a tremendous success – and a great example of how The Society is evolving to meet the needs of our members and the demands of a fast-changing industry.
My theme for this year as President of The Aesthetic Foundation is “to make a difference”. The Foundation is in a unique position as the research, education, and charitable arm of The Aesthetic Society to achieve that goal.